According to the San Francisco, US-based firm the database provides life science customers with details of healthcare professionals and organisations in the UK. Veeva plans to add data from France, Germany, Italy and Spain early next year
Gillaume Roussel, Veeva’s European strategy director, predicted that drug and biopharma firms targeting markets across the region would value a single source data system.
“With a foundation of better data from the Veeva Network Provider Database, life sciences companies can be more responsive and connect with customers across channels.
“Now with a central source for customer and affiliations data across borders, they have the transparency and holistic view needed to improve engagement and help ensure compliance.”
The tech driving the new database – which was launched at the firm’s European Commercial Summit - was developed establishing similar systems in the US and China which, according, to Veeva, house details of more than 10 million healthcare providers.
This pedigree was touched on by Tim Slevin, Veeva’s newly appointed senior VP of global data solutions, who said: “We have a great start, with the most robust industry data in the US and China. I’m thrilled to be part of the continued advancement of Veeva’s data business and help take it to the next level.”
Big Data and cloud-based have been buzzwords in the drug industry for the last few year, beginning in 2013 at events like DIA where Veeva, Medidata, Comprehend Systems and Datatrack International were keen to highlight their technologies.
More recently, generalist services providers have made inroads. In October, for example, inVentiv signed up to provide its customers with access to Veeva’s eTMF technology and Novartis asked Covance to help manage its data.